Indian pharma maker of branded generics in emerging markets and US generics, focused on respiratory, dermatology and diabetes.
Indian pharma maker of branded generics in emerging markets and US generics, focused on respiratory, dermatology and diabetes.
Sells branded and generic medicines, with India and emerging markets giving the steadier income and US generics adding volume. In 2023 it sold most of its active-ingredient business, Glenmark Life Sciences, to Nirma. A blood-cancer antibody from its innovation arm, Ichnos, was licensed to AbbVie in 2025.
In one line: India's smaller Teva with a biologics spin-off.
Moat: narrow (brand, distribution). Established respiratory/dermatology brands in India and a filed US generics pipeline.
Headquarters: Mumbai, India · Founded: 1977 · Employees: 17,782
Size Glenmark Pharmaceuticals (GLENMARK.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $7.98B, the 146th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,646 on 18 Nov 2026.
Performance Over six months the shares gained 10.0%, against +4.4% for the median peer and +3.8% for the India market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 0.1% over the last twelve months (peer median +15.7%); the operating margin is 16.6% (peer median 13.8%).
Valuation It trades at 33.1× forward earnings against a peer median of 19.2× (6th most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.4 points above its cost of capital (13.1% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹159B | ₹170B | ₹133B | ₹118B | ₹116B |
| Revenue growth | — | +27% | +13% | +2% | — |
| Gross profit | ₹65.7B | ₹74.6B | ₹48.2B | ₹32.6B | ₹36.3B |
| EBITDA | ₹33.0B | ₹40.2B | ₹23.8B | ₹12.3B | ₹16.7B |
| Net income | ₹14.5B | ₹13.6B | ₹10.5B | -₹15.0B | ₹2.97B |
| Free cash flow | n/a | ₹19.4B | -₹17.3B | -₹16.6B | -₹2.71B |
| Capital expenditure | n/a | ₹13.6B | ₹7.51B | ₹9.15B | ₹6.08B |
| Total debt | ₹14.1B | ₹5.94B | ₹24.7B | ₹12.3B | ₹46.1B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals GLENMARK.NS | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
| Lupin LUPIN.NS | $9.67B | -14% | +24% | 24% | 21.0× | 8.8% |
| Torrent Pharmaceuticals TORNTPHARM.NS | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% |
| Alembic Pharmaceuticals APLLTD.NS | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GLENMARK.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.7% | +1.7% | 3rd highest of 21 |
| 6-month return | +10.0% | +4.4% | 10th highest of 21 |
| Distance from 52-week high | -2.5% | -13.5% | 2nd highest of 21 |
| Revenue growth (TTM) | -0.1% | +15.7% | 3rd lowest of 21 |
| Operating margin | 16.6% | 13.8% | 8th highest of 20 |
| Forward P/E | 33.1× | 19.2× | 6th most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 27.3% | 8.8% | 2nd most demanding of 13 |
| Growth delivered (Del g) | +9.4% | +9.0% | 6th highest of 13 |
| Hurdle (Req g minus delivered) | +17.9 pp | -2.7 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | +4.4 pp | +1.6 pp | 7th highest of 18 |
| EV / EBITDA | 22.6× | 19.1× | 7th cheapest of 13 |
| Net debt / EBITDA | 0.0× | -0.1× | 7th least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $7.74B | -15% | +10% | 6% | 9.0× | 19.9% | +5.8% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% | +8.1% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 37.4× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $9.16B | +69% | +9% | 26% | n/a | -6.6% | +6.6% |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 81.5× | n/a | n/a |